The phosphoinositide 3-kinase pathway and therapy resistance in cancer.
AuthorBrown, KK; Toker, A
Source TitleF1000prime reports
PublisherFaculty Opinions Ltd
University of Melbourne Author/sBrown, Kristin
AffiliationBiochemistry and Molecular Biology
Document TypeJournal Article
CitationsBrown, K. K. & Toker, A. (2015). The phosphoinositide 3-kinase pathway and therapy resistance in cancer.. F1000Prime Rep, 7, pp.13-. https://doi.org/10.12703/P7-13.
Access StatusOpen Access
Open Access at PMChttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335789
The phosphoinositide 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling network is a master regulator of processes that contribute to tumorigenesis and tumor maintenance. The PI3K pathway also plays a critical role in driving resistance to diverse anti-cancer therapies. This review article focuses on mechanisms by which the PI3K pathway contributes to therapy resistance in cancer, and highlights potential combination therapy strategies to circumvent resistance driven by PI3K signaling. In addition, resistance mechanisms that limit the clinical efficacy of small molecule inhibitors of the PI3K pathway are discussed.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References